1月9日，港通医疗跌5.02%，截至发稿，报24.20元/股，成交2.05亿元，换手率13.05%，总市值24.20亿 元。 诺安多策略混合A（320016）成立日期2011年8月9日，最新规模18.55亿。今年以来收益2.79%，同类排 名4045/8827；近一年收益80.52%，同类排名423/8084；成立以来收益239.2%。 诺安多策略混合A（320016）基金经理为孔宪政。 截至发稿，孔宪政累计任职时间5年45天，现任基金资产总规模56.08亿元，任职期间最佳基金回报 86.44%， 任职期间最差基金回报-16.74%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，四川港通医疗设备集团股份有限公司位于四川省成都市简阳市凯力威工业大道南段356号， 成立日期1998年1月13日，上市日期2023年7月25日，公司主营业务涉及为医疗机构提供以医用气体系统 及医院洁净手术部为核心的医疗专业工程整体方案。主营业务收入构成为：医用洁净 ...

融券方面，港通医疗1月5日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年60%分位水平，处于较高位。 资料显示，四川港通医疗设备集团股份有限公司位于四川省成都市简阳市凯力威工业大道南段356号， 成立日期1998年1月13日，上市日期2023年7月25日，公司主营业务涉及为医疗机构提供以医用气体系统 及医院洁净手术部为核心的医疗专业工程整体方案。主营业务收入构成为：医用洁净装备及系统 55.69%，医用气体装备及系统37.30%，医疗设备及其他产品销售4.06%，运维服务2.81%，其他(补 充)0.14%。 来源：新浪证券-红岸工作室 1月5日，港通医疗涨14.16%，成交额2.18亿元。两融数据显示，当日港通医疗获融资买入额2265.94万 元，融资偿还866.96万元，融资净买入1398.99万元。截至1月5日，港通医疗融资融券余额合计4244.52 万元。 融资方面，港通医疗当日融资买入2265.94万元。当前融资余额4244.52万元，占流通市值的2.66%，融 资余额超过近一年70%分位水平，处于较高位。 分红方面 ...

来源：新浪证券-红岸工作室 12月31日，港通医疗涨0.30%，成交额1821.07万元。两融数据显示，当日港通医疗获融资买入额100.37 万元，融资偿还177.46万元，融资净买入-77.09万元。截至12月31日，港通医疗融资融券余额合计 2845.54万元。 融券方面，港通医疗12月31日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年60%分位水平，处于较高位。 资料显示，四川港通医疗设备集团股份有限公司位于四川省成都市简阳市凯力威工业大道南段356号， 成立日期1998年1月13日，上市日期2023年7月25日，公司主营业务涉及为医疗机构提供以医用气体系统 及医院洁净手术部为核心的医疗专业工程整体方案。主营业务收入构成为：医用洁净装备及系统 55.69%，医用气体装备及系统37.30%，医疗设备及其他产品销售4.06%，运维服务2.81%，其他(补 充)0.14%。 截至12月19日，港通医疗股东户数7539.00，较上期增加2.50%；人均流通股8362股，较上期减少 2.44%。2025年1月-9月，港通医疗实现 ...

12月26日，港通医疗跌1.17%，成交额1741.62万元。两融数据显示，当日港通医疗获融资买入额361.35 万元，融资偿还348.69万元，融资净买入12.66万元。截至12月26日，港通医疗融资融券余额合计 2931.11万元。 来源：新浪证券-红岸工作室 机构持仓方面，截止2025年9月30日，港通医疗十大流通股东中，诺安多策略混合A（320016）位居第 八大流通股东，持股72.51万股，为新进股东。 融资方面，港通医疗当日融资买入361.35万元。当前融资余额2931.11万元，占流通市值的2.08%，融资 余额低于近一年10%分位水平，处于低位。 截至12月19日，港通医疗股东户数7539.00，较上期增加2.50%；人均流通股8362股，较上期减少 2.44%。2025年1月-9月，港通医疗实现营业收入3.44亿元，同比减少30.06%；归母净利润-1020.84万 元，同比减少150.92%。 分红方面，港通医疗A股上市后累计派现4899.73万元。 融券方面，港通医疗12月26日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0 ...

Group 1 - The core viewpoint of the news is that 港通医疗 (Kangtong Medical) is experiencing a decline in stock performance and financial metrics, with significant decreases in revenue and net profit reported for the year 2025 [1][2] - As of December 17, 港通医疗's stock price fell by 0.71%, with a trading volume of 16.32 million yuan, and a net financing buy of -1.29 million yuan, indicating a negative sentiment among investors [1] - The financing balance of 港通医疗 is 27.04 million yuan, which accounts for 1.98% of its market capitalization, indicating a low level of financing compared to the past year [1] Group 2 - For the period from January to September 2025, 港通医疗 reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a significant decline of 150.92% [2] - The company has distributed a total of 48.99 million yuan in dividends since its A-share listing [3] - As of September 30, 2025, the number of shareholders for 港通医疗 is 7,355, a decrease of 1.68%, while the average circulating shares per person increased by 1.71% to 8,571 shares [2]

Group 1 - The core viewpoint of the news is that Kangtong Medical has shown a decrease in financing activities and a significant drop in revenue and net profit for the year 2025 [1][2] - As of December 15, Kangtong Medical's financing balance is 28.75 million yuan, accounting for 2.07% of its market capitalization, which is below the 10th percentile level over the past year, indicating a low financing level [1] - The company reported a revenue of 344 million yuan for the period from January to September 2025, representing a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a decline of 150.92% year-on-year [2] Group 2 - Kangtong Medical's main business includes providing medical gas systems and clean operating room solutions, with revenue composition being 55.69% from clean equipment and systems, 37.30% from medical gas equipment, and 4.06% from other medical device sales [1] - As of December 10, the number of shareholders for Kangtong Medical is 7,355, a decrease of 1.68% from the previous period, while the average circulating shares per person increased by 1.71% to 8,571 shares [2] - The company has distributed a total of 48.99 million yuan in dividends since its A-share listing [3]

Group 1 - The core viewpoint of the news is that 港通医疗 (Kangtong Medical) is experiencing a decline in stock performance and financial metrics, with a notable drop in revenue and net profit [1][2] - On December 10, 港通医疗's stock fell by 2.09%, with a trading volume of 19.84 million yuan, and a net financing purchase of 397,600 yuan [1] - The company's financing balance is 29.25 million yuan, accounting for 2.00% of its market capitalization, which is below the 10th percentile level over the past year, indicating a low financing level [1] Group 2 - As of November 28, the number of shareholders for 港通医疗 decreased by 5.24% to 7,481, while the average circulating shares per person increased by 5.53% to 8,426 shares [2] - For the period from January to September 2025, 港通医疗 reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a decline of 150.92% [2] - 港通医疗 has distributed a total of 48.99 million yuan in dividends since its A-share listing [3]

Core Viewpoint - The financial performance of Kangtong Medical shows a significant decline in revenue and net profit, indicating potential challenges for the company in the near future [2]. Group 1: Financial Performance - As of November 28, 2025, Kangtong Medical reported a revenue of 344 million yuan, a year-on-year decrease of 30.06% [2]. - The company recorded a net profit of -10.21 million yuan, reflecting a year-on-year decrease of 150.92% [2]. - Cumulative cash dividends since the A-share listing amount to 48.9973 million yuan [3]. Group 2: Shareholder and Market Activity - As of December 3, 2025, the number of shareholders for Kangtong Medical is 7,481, a decrease of 5.24% from the previous period [2]. - The average number of circulating shares per shareholder is 8,426, which has increased by 5.53% compared to the last period [2]. - On December 3, 2025, the stock price of Kangtong Medical fell by 0.72%, with a trading volume of 19.146 million yuan [1]. Group 3: Financing and Margin Trading - On December 3, 2025, Kangtong Medical had a financing buy-in of 543,400 yuan, with a net financing buy of -148,120 yuan [1]. - The total financing and margin trading balance for Kangtong Medical is 29.0609 million yuan, with the financing balance accounting for 1.90% of the circulating market value [1]. - The company’s margin trading balance is at a high level, with a margin balance of 2,197 yuan and a margin stock quantity of 100 shares [1]. Group 4: Business Overview - Kangtong Medical, established on January 13, 1998, is located in Chengdu, Sichuan Province, and was listed on July 25, 2023 [1]. - The company's main business involves providing medical institutions with overall solutions centered on medical gas systems and clean operating rooms [1]. - The revenue composition includes: 55.69% from clean medical equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from medical equipment and other product sales, 2.81% from operation and maintenance services, and 0.14% from other sources [1].

Group 1 - The core viewpoint of the news is that 港通医疗 (Kangtong Medical) is experiencing a decline in financial performance, with significant decreases in both revenue and net profit year-on-year [2] - As of December 2, 港通医疗's stock price decreased by 0.23%, with a trading volume of 22.5 million yuan, and a net financing purchase of 518,800 yuan [1] - The company's financing balance is 30.54 million yuan, which is 1.98% of its market capitalization, indicating a low level compared to the past year [1] Group 2 - 港通医疗's revenue for the period from January to September 2025 was 344 million yuan, representing a year-on-year decrease of 30.06% [2] - The company reported a net profit attributable to shareholders of -10.21 million yuan, a significant decline of 150.92% compared to the previous year [2] - The company has distributed a total of 48.99 million yuan in dividends since its A-share listing [3] Group 3 - As of November 28, 港通医疗 had 7,481 shareholders, a decrease of 5.24% from the previous period, while the average number of circulating shares per person increased by 5.53% to 8,426 shares [2] - The top ten circulating shareholders include 诺安多策略混合A (Noah Multi-Strategy Mixed A), which holds 725,100 shares as a new shareholder [3] - The company's main business involves providing medical institutions with overall solutions centered on medical gas systems and clean operating rooms, with revenue contributions of 55.69% from clean equipment and systems, 37.30% from medical gas equipment and systems, and 4.06% from other medical equipment sales [1]

Group 1 - The core point of the news is that 港通医疗 (Kangtong Medical) experienced a decline of 5.04% in its stock price, reaching 21.29 CNY per share, with a total market capitalization of 2.129 billion CNY as of the report date [1] - The company, established on January 13, 1998, and listed on July 25, 2023, specializes in providing medical gas systems and clean surgical room solutions to healthcare institutions [1] - The revenue composition of the company includes: 55.69% from clean medical equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from medical device sales, 2.81% from operation and maintenance services, and 0.14% from other sources [1] Group 2 - Among the top ten circulating shareholders of 港通医疗, 诺安多策略混合A (Noah Multi-Strategy Mixed A) fund has recently entered the list, holding 725,100 shares, which accounts for 1.15% of the circulating shares [2] - The fund, established on August 9, 2011, has a current size of 1.855 billion CNY and has achieved a year-to-date return of 73.37%, ranking 205 out of 8,136 in its category [2] - The fund manager, 孔宪政 (Kong Xianzheng), has a tenure of nearly 5 years, with the best fund return during this period being 95.2% and the worst being -16.74% [3]